Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Skin side effects from CDK4/6 inhibitors in breast cancer patients are generally mild and treatable, allowing most patients to continue treatment.

Chronic telogen effluvium may not be a unique condition and could be confused with other types of hair loss.

A new treatment called deucravacitinib helped a patient with severe hair loss grow their hair back quickly.

The AI system HairComb accurately scores hair loss severity, matching dermatologist assessments.

The symposium highlighted the skin's role in sensing itch, pain, touch, and pleasure, and discussed new research and techniques for understanding and treating these sensations.

UVFT helps diagnose hair and scalp diseases by showing different fluorescence patterns.

Exosomes may help with hair growth and scar healing, but more research is needed.

Exosomes are important for skin treatments and hair growth but need more research for safe and effective use.

Clascoterone cream effectively reduces acne severity and is safe for patients 12 and older.

Alopecia areata patients show increased inflammation and OX40 activation, suggesting a new treatment target.

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Injecting fillers in the temple can cause serious complications, but the damage can be treated if managed properly.

Wigs help improve self-esteem and quality of life for people with hair loss from alopecia areata.

Minoxidil improved hair growth in a child with a rare genetic disorder.

Patients with certain skin diseases are willing to spend significant time on treatment, indicating a high impact on their lives and a need for better treatments.

Refugee patients face long wait times for dermatology care, worsening health disparities.

Finasteride and dutasteride are effective in treating male hair loss but can cause sexual side effects and birth defects.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Assessing CD8+ T cell levels before surgery may improve vitiligo treatment outcomes.

The analysis found that alopecia areata, a hair loss condition, is not very common in Australia, affecting about 0.13% of people, with new cases most often seen in males aged 19 to 34 years.

Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.

Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.

Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.

The research found a way to grow plant tissue and analyze compounds in Bituminaria bituminosa, which is promising for hair restoration treatments.

Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.

Women with frontal fibrosing alopecia have similar vitamin D levels to those with other hair loss types, suggesting vitamin D is not a key factor in this condition.

The conclusion is that women are heavily affected by autoimmune skin diseases, face significant challenges, and need better research, treatments, and healthcare policies.